CL2024000232A1 - Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma - Google Patents
Composición farmacéutica de anticuerpo anti-pd-1 y uso de la mismaInfo
- Publication number
- CL2024000232A1 CL2024000232A1 CL2024000232A CL2024000232A CL2024000232A1 CL 2024000232 A1 CL2024000232 A1 CL 2024000232A1 CL 2024000232 A CL2024000232 A CL 2024000232A CL 2024000232 A CL2024000232 A CL 2024000232A CL 2024000232 A1 CL2024000232 A1 CL 2024000232A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical composition
- seq
- antibody
- antigen
- amino acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona una composición farmacéutica de anticuerpo anti-PD-1 estable y el uso de la misma. La composición farmacéutica comprende un tampón y un anticuerpo anti-PD-1 o un fragmento de unión a antígeno del mismo; en donde el anticuerpo anti-PD-1 o el fragmento de unión a antígeno del mismo tiene una concentración de aproximadamente 100-250 mg/ml y comprende una LCDR1, una LCDR2 y una LCDR3 que tienen las secuencias de aminoácidos establecidas en la SEQ ID NO: 1, SEQ ID NO: 2 y SEQ ID NO: 3, respectivamente, y una HCDR1, una HCDR2 y una HCDR3 que tienen secuencias de aminoácidos establecidas en la SEQ ID NO: 4, SEQ ID NO: 5 y SEQ ID NO: 6, respectivamente; y en donde la composición farmacéutica tiene un pH de aproximadamente 5.0-6.5. La presente invención también proporciona una inyección que comprende la composición farmacéutica y el uso de la composición farmacéutica y la inyección en la preparación de un medicamento para tratar una enfermedad o trastorno eliminando, inhibiendo o reduciendo la actividad de PD-1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110863978 | 2021-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024000232A1 true CL2024000232A1 (es) | 2024-07-26 |
Family
ID=85086307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000232A CL2024000232A1 (es) | 2021-07-29 | 2024-01-26 | Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240342083A1 (es) |
| EP (1) | EP4376809A4 (es) |
| JP (1) | JP2024528724A (es) |
| CN (1) | CN116019907A (es) |
| AR (1) | AR126614A1 (es) |
| AU (1) | AU2022320670A1 (es) |
| CA (1) | CA3227991A1 (es) |
| CL (1) | CL2024000232A1 (es) |
| MX (1) | MX2024001326A (es) |
| UY (1) | UY39878A (es) |
| WO (1) | WO2023006055A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113244386A (zh) * | 2020-02-13 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗肿瘤中的用途 |
| WO2025013783A1 (ja) * | 2023-07-07 | 2025-01-16 | ナガセヴィータ株式会社 | タンパク質の変性抑制用組成物 |
| WO2025113598A1 (zh) * | 2023-12-01 | 2025-06-05 | 齐鲁制药有限公司 | 稳定的混合抗体的药物组合物 |
| WO2025140495A1 (zh) * | 2023-12-28 | 2025-07-03 | 齐鲁制药有限公司 | 稳定的抗pd-1抗体的药物组合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104250302B (zh) * | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| MX2019010999A (es) * | 2017-03-29 | 2020-02-05 | Celgene Corp | Formulaciones que comprenden proteinas de union a pd-1 y metodos para preparar las mismas. |
| MY195465A (en) * | 2017-05-16 | 2023-01-25 | Jiangsu Hengrui Medicine Co | PD-L1 Antibody Pharmaceutical Composition and use Thereof |
| CN111246886B (zh) * | 2017-11-02 | 2022-03-15 | 正大天晴药业集团股份有限公司 | 一种抗pd-l1人源化单克隆抗体的药物组合物 |
| CN110882385B (zh) * | 2018-09-07 | 2021-07-09 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗肿瘤中的用途 |
| JP7491220B2 (ja) * | 2018-11-27 | 2024-05-28 | 小野薬品工業株式会社 | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 |
| CN112741804A (zh) * | 2019-10-31 | 2021-05-04 | 上海君实生物医药科技股份有限公司 | 含有抗pd-l1抗体的稳定制剂 |
| WO2022152245A1 (zh) * | 2021-01-14 | 2022-07-21 | 上海君实生物医药科技股份有限公司 | 抗tigit抗体药物组合物及其用途 |
-
2022
- 2022-07-29 CN CN202210929845.3A patent/CN116019907A/zh active Pending
- 2022-07-29 JP JP2024505015A patent/JP2024528724A/ja active Pending
- 2022-07-29 AU AU2022320670A patent/AU2022320670A1/en active Pending
- 2022-07-29 US US18/291,935 patent/US20240342083A1/en active Pending
- 2022-07-29 EP EP22848659.3A patent/EP4376809A4/en active Pending
- 2022-07-29 MX MX2024001326A patent/MX2024001326A/es unknown
- 2022-07-29 AR ARP220102031A patent/AR126614A1/es unknown
- 2022-07-29 CA CA3227991A patent/CA3227991A1/en active Pending
- 2022-07-29 WO PCT/CN2022/108825 patent/WO2023006055A1/en not_active Ceased
- 2022-07-29 UY UY0001039878A patent/UY39878A/es unknown
-
2024
- 2024-01-26 CL CL2024000232A patent/CL2024000232A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022320670A1 (en) | 2024-03-14 |
| MX2024001326A (es) | 2024-02-15 |
| CN116019907A (zh) | 2023-04-28 |
| AR126614A1 (es) | 2023-10-25 |
| CA3227991A1 (en) | 2023-02-02 |
| JP2024528724A (ja) | 2024-07-30 |
| UY39878A (es) | 2023-02-28 |
| WO2023006055A1 (en) | 2023-02-02 |
| EP4376809A4 (en) | 2025-06-04 |
| EP4376809A1 (en) | 2024-06-05 |
| US20240342083A1 (en) | 2024-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024000232A1 (es) | Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma | |
| PE20240363A1 (es) | Anticuerpos anti-ccr8 y usos de los mismos | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| RU2486198C2 (ru) | Антиген, ассоциированный с ревматоидным артритом | |
| PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
| AR079903A1 (es) | Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit. | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| AR081434A1 (es) | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo | |
| FI3653225T3 (fi) | Menetelmät migreenipäänsäryn hoitamiseksi tai ehkäisemiseksi käyttämällä cgrp-reseptoriin kohdistuvia vasta-aineita | |
| RU2013148537A (ru) | Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения | |
| JP2015526440A5 (es) | ||
| NZ706986A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| AR071891A1 (es) | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) | |
| IL259036A (en) | asct2-specific binding molecules and their uses | |
| RU2015110981A (ru) | Комбинации и их применение | |
| JP2023055904A5 (es) | ||
| PE20141706A1 (es) | Anticuerpos de union a trombina y usos del mismo | |
| PE20201503A1 (es) | Formulaciones de inmunoconjugado anti-cd79b estables | |
| AR124067A2 (es) | Formulaciones estables que comprenden un anticuerpo biespecífico para egfr / c-met | |
| AR124914A1 (es) | Nuevo anticuerpo anti-pad4 | |
| CL2024002975A1 (es) | Anticuerpo biespecífico anti-tigit y anti-pvrig, composición farmacéutica del mismo, y uso del mismo | |
| FI3630177T3 (fi) | Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle | |
| MX2024015541A (es) | Anticuerpo anti-cldn18.2, y composicion farmaceutica y uso de la misma |